Kornimate/medical-research-clean huggingface dataset:
1-year clinical outcomes in recombinant tissue plasminogen activator (rt-pa) treated chinese acute ischaemic stroke (ais) patients

Conditions: Stroke

Summary: the objective of the study is to find out the 1-year clinical outcomes among acute ischaemic stroke (ais) patients who were treated with intravenous (iv) recombinant tissue plasminogen activator (rt-pa) within 4.5 hours of symptom onset compared with those who arrived or were admitted to the hospital within 4.5 hours of symptom onset and did not receive any reperfusion treatment in a real-world clinical setting.


Eligibility criteria:
inclusion criteria: * patients registered in the zsqcc platform from jan 2017 to mar 2020 * ≥ 18 years of age * diagnosed with ais at admission * arrived or admitted to the hospital within 4.5 hours of symptom onset * if treated with iv rt-pa: received iv rt-pa within 4.5 hours of symptom onset exclusion criteria: * documented intravenous thrombolysis (ivt) contraindication except age to iv rt-pa treatment according to the summary of product characteristics (smpc) * missing any one of the key data (age, gender, baseline national institutes of health stroke scale \[nihss\], time of symptom onset, time of hospital arrival or admission, ivt or not, time of iv rt-pa treatment) * received thrombolysis agents other than rt-pa (urokinase, tenecteplase, recombinant plasminogen activator, prourokinase, streptokinase) * received endovascular treatment * received iv rt-pa after 4.5 hours of symptom onset
safety and efficacy of longterm hpn with two lipid emulsions

Conditions: Malnutrition

Summary: it is the purpose of this trial to provide evidence for safety and efficacy of long term home parenteral nutrition with either lipofundin mct or lipoplus in patients with proven insufficient enteral resorption.

long term parenteral nutrition is indicated in the home care setting of patients who are unable to completely cover their daily caloric requirements by oral/enteral nutrition due to e.g. pre existing malnutrition or compromised intestinal absorption. an appropriate nutritional supplementation ensuring the provision of patients basic requirement of amino acids, glucose, lipids, micronutrients and electrolytes is therefore required to stop weight loss, increase quality of life and to reduce unfavorable consequences of malnutrition in those patients. major causes for malnutrition and compromised intestinal absorption are malignant processes. tumor cachexia, weight loss due to insufficient nutrition of \ 14 days, antineoplastic therapy and surgical intervention are consequences of the malignant disease and lead to catabolic processes.

Eligibility criteria:
inclusion criteria: * signed informed consent * age: 18-80 years * male and female patients * patients with a newly indicated need of long-term home parenteral nutrition (hpn) for at least 8 weeks * patients with an insufficient resorption capacity of the colon that may not be compensated by enteral nutrition * mentally and physically able to adhere to study procedures. * females agree to apply adequate contraception exclusion criteria: * participation in a clinical study with an investigational drug within one month prior to the start of study * patients with sepsis, severe sepsis and septic shock * known or suspected drug abuse * general contra indications for infusion therapy such as acute pulmonary edema, hyperhydration and decompensated cardiac insufficiency * pregnancy and lactation * autoimmune disease as e.g. hiv * known hypersensitivity to egg-, soy-, and fish proteins or any of the ingredients * hemodynamic failure of any origin (hemorrhagic shock, myocardial infarction, cardiac failure) * alterations of coagulation (thrombocytes \ 40 sec * diabetes mellitus with known ketoacidosis within 7 days before onset of study * renal insufficiency with serum creatinine \> 1.4 mg/dl(\>124 mmol/l) * patients with severe liver dysfunction with bilirubin \>2.5 mg/dl (\> 43 µmol/l) * lipid disorders, in particular fasting serum triglycerides \> 250 mg/dl (\>2.86 mmol/l) * necrotizing pancreatitis

Keywords: hpn lipid emulsion long term insufficient enteral resorption capacity
hydraulic resistance and older adults

Conditions: Aging; Fall; Old Age; Debility; Muscle Weakness

Summary: the goal of this quasi-experimental study using a pre and post test design is to learn about the effect of participating in an exercise program with hydraulic exercise equipment on fall risk in the older adult population. the main questions it aims to answer are: * does the use of hydraulic exercise equipment decrease fall risk in older adults? * does the use of hydraulic exercise equipment improve function in older adults? participants will be evaluated pre and post intervention for strength, fall risk using berg balance scale, tinetti balance and gait assessment, timed up and go, and functional ability using the lower extremity functional scale. participants will engage in an exercise program using 5 different pieces of hydraulic exercise equipment (frei factum® novus ii line) 2x/week for for 6 weeks for 30-45 minutes each session. the equipment uses concentric movements only and works agonist and antagonist muscles with each machine (ie: push and pull, both concentric).


Eligibility criteria:
inclusion criteria: * healthy adults * age 60+ exclusion criteria: * age \<60 * neurological condition * surgery within last 6 months * current injury * inability to follow directions * inability to participate in physical activity for any medical reason
web-based interventions on nonalcoholic fatty liver disease (nafld) in obese children

Conditions: NAFLD; Web; Childhood Obesity

Summary: the web-based continuity of care intervention model to provide comprehensive nursing interventions for obese children with nafld, always tracking their performance status, enabling them to grasp the knowledge of healthy weight loss, develop good lifestyle habits, and reduce their weight, thus reducing the incidence of nafld in children.

the web-based continuity of care intervention model to provide comprehensive nursing interventions for obese children with nafld, always tracking their performance status, enabling them to grasp the knowledge of healthy weight loss, develop good lifestyle habits, and reduce their weight, thus reducing the incidence of nafld in children.the primary outcome are serum biomarkers such as alanine aminotransferase (alt) and gamma-glutamyl transferase (ggt) . second outcomes are: aspartate aminotransferase, and liver imaging (liver ultrasound and magnetic resonance imaging), bmi, waist-to-hip ratio and quality of life. in addition, socio-demographic characteristics such as age, gender and ethnicity will be recorded. all outcomes were measured at baseline, week 4, week 16, week 24, week 36, and week 48 to determine the trajectory of change in outcome variables over intervention process.

Eligibility criteria:
inclusion criteria: * the clinical diagnosis of nonalcoholic fatty liver disease exclusion criteria: * patients do not agree to participate * participate in other health intervention programs now

Keywords: nafld obese children web education protocol
the influence of muscle contraction on the cardiac autonomic system

Conditions: Cerebral Palsy

Summary: population: 16 children with cerebral palsy, gmfcs 1-3.16 children typically developed, matched for age. all children aged 6-12 yrs who understand simple commands. tools: 1. polar monitor to record heart rate, attached to chest, in use throughout testing 2. dynamometer- for assessing muscle strength. 3. weights method: each child will be tested once. both tools will be demonstrated and tried out before actual testing. with polar watch attached: 1. 5 min sitting at rest, 2. knee muscle strength assessment with the dynamometer, 3. 15 minutes rest 4. isometric and isotonic knee muscle contraction at 30% of childs' maximal strength as has assessed by the dynamometer. the child will asked to perform each for 3 minutes, with 5 minutes rest in-between all will be perform in both legs.


Eligibility criteria:
inclusion criteria: * gmfcs i-ii * unilateral cp exclusion criteria: * heart problems
safety and efficacy of sof/vel/vox fdc for 8 weeks and sof/vel for 12 weeks in adults chronic genotype 3 hcv infection and cirrhosis

Conditions: Hepatitis C Virus Infection

Summary: the primary objective of this study is to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (sof/vel/vox) fixed-dose combination (fdc) for 8 weeks and of treatment with sofosbuvir/velpatasvir (sof/vel) fdc for 12 weeks in participants naive to direct-acting antivirals (daa) with chronic genotype 3 hepatitis c virus (hcv) infection and cirrhosis.


Eligibility criteria:
key inclusion criteria: * willing and able to provide written informed consent * hcv rna ≥ 10\^4 iu/ml at screening * chronic genotype 3 hcv infection (≥ 6 months) * presence of cirrhosis * hcv treatment naive or treatment experienced with an interferon (ifn)-based regimen * use of protocol specified methods of contraception key exclusion criteria: * current or prior history of clinically significant illness that may interfere with participation in the study * screening ecg with clinically significant abnormalities * laboratory parameters outside the acceptable range at screening * pregnant or nursing female * chronic liver disease not caused by hcv * infection with hepatitis b virus (hbv) or human immunodeficiency virus (hiv) note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: chronic
trial of single microneedle radiofrequency for moderate-to-severe acne vulgaris

Conditions: Acne Vulgaris

Summary: the purpose of the study is to testify the efficacy of treating moderate-to-severe acne vulgaris with single microneedle radiofrequency, and provide evidence for the hypothesis that "whether single microneedle radiofrequency therapy could be an alternative to photodynamic therapy for moderate to severe acne vulgaris."

the purpose of the study is to testify whether single microneedle radiofrequency is effective for moderate-to-severe acne vulgaris, through treating moderate-to-severe acne vulgaris patient for 1 month, using photodynamic therapy as controlled group, and try to provide clinical evidence for the hypothesis that "whether single microneedle radiofrequency therapy could be an alternative to photodynamic therapy for moderate to severe acne vulgaris."

Eligibility criteria:
inclusion criteria: 1. consistent with the diagnostic criteria of moderate-to-severe acne vulgaris (iga3-4) . 2. age of a subject is older than 14 and is younger than 45.（including 14 and 45）. 3. did not take any anti-acne treatment in the last 1 month, and did not take part in any clinical trial. 4. informed consent is signed by a subject or his lineal relation. exclusion criteria: 1. systemic acne treatment with oral isotretinoin within 6 months or oral antibiotics in the past 1 month; 2. history of facial procedures like dermabrasion, chemical, or laser peels; 3. history of photosensitive diseases, porphyria, or porphyrin sensitivity. 4. with serious protopathy or disease of cardiovascular, liver, renal, gastrointestinal, hematological systems and so on. 5. pregnant women or women in lactation.
efficacy and safety study on agilis nxt introducer in af patients

Conditions: Atrial Fibrillation

Summary: to prove if the success rate of curative treatment of atrial fibrillation in left atrial circumferential pulmonary vein ablation is higher by using a steerable transseptal introducer giving access to the left atrium then by using a conventionally introducer with fixed curve.

to prove if the success rate of curative treatment of atrial fibrillation in left atrial circumferential pulmonary vein ablation is higher by using a steerable transseptal introducer giving access to the left atrium then by using a conventionally introducer with fixed curve; in patients with paroxysmal or persistent symptomatic atrial fibrillation. primary endpoint: rate of patients in stable sinus rhythm at 6 month follow up

Eligibility criteria:
inclusion criteria: * paroxysmal or persistent symptomatic atrial fibrillation * resistant to at least 1 anti arrhythmic drug * left atrial diameter less then 60 mm (tte, parasternal) * atrial fibrillation documented by ecg * patient is willing and available to perform all follow ups exclusion criteria: * permanent atrial fibrillation * pre existing left atrial fibrillation ablation * atrial fibrillation due to reversible cause * known intracardiac or other thrombi * pregnancy * women of child bearing potential without negative pregnancy test within 48 hours prior to ablation * contraindication for anticoagulation

Keywords: atrial fibrillation paroxysmal persistent symptomatic ablation catheter introducer agilis nxt sinus rhythm paroxysmal atrial fibrillation persistent atrial fibrillation symptomatic atrial fibrillation
the effect of intracameral cefuroxime on post-op fibrin in pediatric cataract surgery

Conditions: Cataract; Endophthalmitis

Summary: the study investigates whether placing an antibiotic inside the eye at the end of cataract surgery in children will reduce the amount of fibrin formation (fibrin formation can block the pupil and reduce vision). we hypothesize that the fibrin is caused by a low-level infection and could be prevented by the antibiotic.

the study investigates whether using an antibiotic (cefuroxime) in the anterior chamber of the eye at the end of surgery for cataract in children will reduce the amount of fibrin formation.

Eligibility criteria:
inclusion criteria: * bilateral congenital or developmental pediatric cataract exclusion criteria: * traumatic cataract

Keywords: fibrin endophthalmitis cataract extraction lens implantation, intraocular
faith-based approaches to treating hypertension and colon cancer prevention

Conditions: Blood Pressure; Colorectal Cancer

Summary: primary aim: to evaluate the effect of a lifestyle intervention delivered through telephone-based motivational interviewing (mint) versus a patient navigation intervention on blood pressure reduction and crc screening. hypotheses: among black men, aged \> 50 years with uncontrolled htn and in need of crc screening: 1. hyp. 1: those randomized to the lifestyle intervention will have lower bp compared to those randomized to the patient navigation intervention at 6 months. 2. hyp. 2: those randomized to the patient navigation intervention will have higher crc screening rates compared to those randomized to the lifestyle intervention at 6 months.

the primary outcomes will be (1) within-patient change in systolic and diastolic bp from baseline to 6 months and (2) crc screening rates as determined by colonoscopy report or fecal immunochemical test (fit) result from the primary care provider at 6 months. blood pressure will be assessed with an automated digital bp monitor based on american heart association guidelines.1 crc screening will be assessed by self-report and verified with medical records and/or the actual colonoscopy or fit report from participants' providers.

Eligibility criteria:
inclusion criteria: * participants must be age 50 years or older * participants must have a working telephone (a necessary criterion since much of the interventions are telephone based) * self-identified as a black or african american and male * have uncontrolled hypertension defined as sbp\>135 mmhg or dbp\>85 mmhg and sbp \>130 mmhg or dbp \>80 mmhg (in those with diabetes) at the screening * have a need for crc screening defined as: 1) no colonoscopy in the last 10 years; 2) no flexible sigmoidoscopy, digital contrast barium enema or ct-colonoscopy in the last 5 years, or 3) no fecal immunochemical test or fecal occult blood test in the last 12 months. * all participants must be fluent in english. certain measures used have not been verified in other languages. exclusion criteria: * inability to comply with the study protocol (either self-selected or by indicating during screening that he could not complete all requested tasks).
the effect of voltaren-ophtha 0.1% eye drops on inr levels (international normalized ratio) in patients taking warfarin

Conditions: Blood Coagulation Disorders

Summary: a prospective study intended to examine the effect of topical voltaren-ophtha 0.1% eye drops after cataract surgery on inr levels (international normalized ratio) in patients taking warfarin.

objective: to examine the effect of topical voltaren-ophtha 0.1% eye drops after cataract surgery on inr levels ( international normalized ratio) in patients taking warfarin. methods: a prospective study. the study population will include approximately 100 patients, taking warfarin and that are candidates for cataract surgery. these patients will continue their warfarin therapy as usual and at the same dose, before and after the operation. inr levels (international normalized ratio) will be checked once a week while taking voltaren eye drops as is customary after cataract surgery.

Eligibility criteria:
inclusion criteria: * people taking warfarin * candidates for cataract surgery exclusion criteria: * age \<18 years * pregnant women

Keywords: warfarin voltaren eye drops inr
proteinuria during acute pyelonephritis in pregnancy

Conditions: Proteinuria

Summary: the purpose of this research study is to compare the amount of protein excreted by the kidneys in a 24-hour period between patients who have a kidney infection and those who do not have a kidney infection.

preeclampsia is a pregnancy-unique disorder that is cured only with delivery of the baby, even if the pregnancy is premature. defined by both blood pressure and proteinuria criteria, diagnosis is often obscured by renal processes like systemic lupus erythematosus or nephrotic syndrome that increase urinary protein spillage. proteinuria is defined as a total protein urinary excretion exceeding 300 mg in a 24-hour urine collection in pregnancy. this is suggested to be double the protein excretion in the non-pregnancy population at 150 mg/day. a mean 24-hour urine protein excretion of 204.3 mg (± 92.5) was found in the non-hypertensive pregnant population. physiological changes in pregnancy predispose patients to urinary tract infections; ureteral compression by the gravid uterus, progesterone-mediated slowing of ureteral peristalsis and decreased bladder tone, and mechanical compression of the bladder contribute to impaired clearance of bacteria from the urinary tract. indeed, acute cystitis complicates 2-4% of all pregnancies. while it has been said that urinary tract infections increase proteinuria, it is unknown how much protein spillage should be expected in the general or the pregnant populations. hence a patient with pyelonephritis may obscure the diagnosis of preeclampsia if she spills urinary protein from her infection. the purpose of this study is to compare the mean of 24-hour urine protein in pregnant patients with and without acute pyelonephritis. the importance of this study will be to determine if urine protein excretion is in fact increased in the setting of pyelonephritis. this will allow for reliable evaluation of urine protein during the work up for preeclampsia in those women also found having a kidney infection.

Eligibility criteria:
inclusion criteria: * women ≥ 18 years old admitted at miller children and women's hospital long beach memorial medical center * gestational age between 20 weeks and 0 days to 41 weeks and 0 days * singleton pregnancy * pyelonephritis group: meeting 2 out of 3 criteria: 1. fever \> 100.4 2. costovertebral angle tenderness 3. positive urine culture - without pyelonephritis group: without acute cystitis and pyelonephritis positive culture defined as: quantitative count of ≥ 100,000 cfu/ml or single catheterized urine specimen with quantitative count of 100 cfu/ml. exclusion criteria: * chronic hypertension * pre-gestational diabetes * autoimmune disorders * preexisting renal disease * multiple gestation * vaginal bleeding * preeclampsia * hospital admission \> 3 days

Keywords: urine protein pregnancy pyelonephritis kidney infection
pufas and left ventricular function in heart failure

Conditions: Dilated Cardiomyopathy; Heart Failure

Summary: the purpose of this study is to test the hypothesis that n-3 pufas improve left ventricular systolic function in patients with stable chronic hf secondary to nonischemic dilated cardiomyopathy (nicm).

the results of the gissi-hf trial indicate that in patients with chronic hf on evidence-based medical therapy and new york heart association (nyha) functional class ii-iv, long term treatment with n-3 pufas 1 g daily reduces mortality and hospitalizations for cardiovascular reasons. several potential mechanisms may underlie the beneficial effects of n-3 polyunsaturated fatty acids (pufas) in hf patients, including, but not limited to, antiarrhythmic, and hemodynamic actions. the current investigation was therefore designed to test the hypothesis that treatment with n-3 pufas improves lv systolic function expressed as ef in patients with stable chronic hf secondary to a nonischemic dilated cardiomyopathy (nicm). additionally, we sought to determine if n-3 pufas also exert positive effects on lv diastolic function assessed by echocardiography; functional capacity assessed by cardiopulmonary stress testing (cpet); and new york heart association (nyha) functional class.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of non ischemic cardiomyopathy (the absence of coronary artery disease,defined as the absence of stenosis \> 50%, was confirmed by angiography performed at the time of the diagnostic workup of the cardiomyopathy) * lv systolic dysfunction (defined as an ef \< 45%) * stable clinical conditions with minimal or no symptoms for at least three month * evidence-based medical treatment at maximum tolerated target doses for at least six month exclusion criteria: * presence of symptoms or evidence of cad diagnosed through noninvasive tests; * peripheral arterial disease; * presence of congenital or primary valvular heart disease; * persistent atrial fibrillation; * inability to perform bicycle ergometry for noncardiac causes; * moderately to severely reduced functional capacity; * nyha functional class iv; * poor acoustic windows limiting the ability to assess echocardiographic measurements; * chronic lung disease; * advanced renal disease (egfr \< 30 ml/min/1.73 m2); * advanced liver disease; * any disease limiting life expectancy to one year or less; * contraindications to study drugs; * concomitant participation in other research studies

Keywords: n-3 pufas heart failure dilated cardiomyopathy ejection fraction exercise capacity